DelveInsight’s “Erosive Esophagitis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Erosive Esophagitis Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Erosive Esophagitis market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Erosive Esophagitis: An Overview
Gastroesophageal reflux disease (GERD) is caused by the abnormal reflux of gastric contents into the esophagus. According to the presence of esophageal mucosal breaks, GERD can be divided into two groups, erosive esophagitis and non-erosive reflux disease (NERD).
According to a study by Richter et al. (2018), “Patients with GERD with the typical reflux syndrome associated with erosive esophagitis and hiatal hernia can have mucosal eosinophilia, which often is confined to the distal esophagus. It is not clear what proportion of patients with GERD present with these features, but it is likely to be less than 10%.” In the same study, it was found that from 2003 to 2006, there were approximately 10,570 hospital admissions annually for erosive esophagitis.
Erosive Esophagitis Market Key Facts
-
According to a study by Joel E. Richter et al., (2018), in the US, estimates of the prevalence of GERD symptoms have ranged from 6% to 30%, with heterogeneity related to the particular questionnaire used, including the threshold frequency and duration of symptoms required to be classified as GERD. The prevalence of at least weekly GERD symptoms in the US is approximately 20%.
-
In persons with GERD symptoms, about 20% are found to have erosive esophagitis, while ulcers or strictures are found in less than 5% of all patients with erosive esophagitis.
-
Up to 90% of Erosive Esophagitis (EE) patients may experience symptomatic relapse within six months of stopping treatment.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Erosive Esophagitis market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report details the Erosive Esophagitis market trend for each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.
Erosive Esophagitis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.
Erosive Esophagitis Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the rate of uptake of the potential drugs recently launched in the Erosive Esophagitis market or expected to be launched during the study period. The analysis covers Erosive Esophagitis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Erosive Esophagitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Request for Sample PDF Report – https://www.delveinsight.com/sample-request/erosive-esophagitis-market
Some of the key companies in the Erosive Esophagitis (EE) market include:
-
Takeda
-
Ironwood Pharma
-
Daewoong Pharmaceutical
-
Luoxin Pharmaceutical
-
Yooyoung Pharmaceutical Co. Ltd.
And others
Erosive Esophagitis (EE) therapies covered in the report include:
-
DWP 14012
-
LXI-15028
-
Vonoprazan
-
YYD601
-
IW-3718
And many more.
Get More Detailed Insights Into the Emerging Therapies & Key Companies – https://www.delveinsight.com/sample-request/erosive-esophagitis-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Erosive Esophagitis Competitive Intelligence Analysis
4. Erosive Esophagitis Market Overview at a Glance
5. Erosive Esophagitis Disease Background and Overview
6. Erosive Esophagitis Patient Journey
7. Erosive Esophagitis Epidemiology and Patient Population
8. Erosive Esophagitis Treatment Algorithm, Current Treatment, and Medical Practices
9. Erosive Esophagitis Unmet Needs
10. Key Endpoints of Erosive Esophagitis Treatment
11. Erosive Esophagitis Marketed Products
12. Erosive Esophagitis Emerging Therapies
13. Erosive Esophagitis Seven Major Market Analysis
14. Attribute Analysis
15. Erosive Esophagitis Market Outlook (7 major markets)
16. Erosive Esophagitis Access and Reimbursement Overview
17. KOL Views on the Erosive Esophagitis Market.
18. Erosive Esophagitis Market Drivers
19. Erosive Esophagitis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report – https://www.delveinsight.com/sample-request/erosive-esophagitis-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Galactosemia Market
“Galactosemia Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Galactosemia Market size, share, and trends in the 7MM. Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics Market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/